Pay in 4 interest-free payments of $6.23 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Reducing dosing frequency from weekly to every two weeks, which cuts total drug exposure in half, only reduced weight loss from approximately 17% to approximately 12%
Concerns about the potential association between certain diabetes medications and cardiovascular disease meant that in 2010 the FDA approved liraglutide on condition that Novo Nordisk conduct a post-marketing study to evaluate the drug's effect on the incidence of major cardiovascular events (Nielsen, DeChiaro, Goldman)
Weekly injection regimens, such as those adopted by some GLP-1 receptor agonists, have already been met with patient preference due to the reduced frequency of administration compared to daily injections like basal insulin
Pharmaceutics 16:886 Kim H-A, Kim J-E (2022) Development of nafamostat mesylate immediate-release tablet by drug repositioning using quality-by-design approach
US$ 22.77
US$ 25.92
US$ 21.61
US$ 26.36
US$ 23.37
US$ 25.43
US$ 29.71
US$ 20.35
